At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our vision as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions.
“At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients.”
There are more than 300 clinical trials at major medical centers worldwide using compounds from Celgene. Investigational compounds are being studied for patients with rare diseases and diseases of unmet medical need. Some of the Canadian trials include Multiple Myeloma (MM), Myelodysplastic Syndromes (MDS), Acute Myelogenous Leukemia (AML), Beta-Thalassemia, Atopic Dermatitis, Psoriatic Arthritis, Psoriasis, Ulcerative Colitis, Crohn’s Disease and Multiple Sclerosis. As committed as we are to clinical accomplishment, we are equally committed to patient support, which is a guiding principle at Celgene. We believe all who can benefit from our discoveries should have the opportunity to do so. Celgene puts patients first with industry-leading programs that provide information, support and access to our innovative therapies.